Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simron Singh

Showing results (111-120 of 141) with videos related to

Pageof 15
Sort By:
The Lancet. Oncology|January 19, 2015
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trialRicard Mesía, Michael Henke, Andre Fortin, et al.
The Oncologist|August 3, 2021
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective ReviewDavid L Chan, Emily K Bergsland, Jennifer A Chan, et al.
Cancer Science|October 22, 2017
Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysisNicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, et al.
JAMA Oncology|October 3, 2024
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENsJonathan M Loree, David Chan, Jennifer Lim, et al.
Genome Medicine|April 30, 2020
Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumorRene Quevedo, Anna Spreafico, Jeff Bruce, et al.
Endocrine-Related Cancer|January 22, 2021
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasmsJames C Yao, Jonathan Strosberg, Nicola Fazio, et al.
NAR Cancer|August 4, 2020
Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data miningJina Nanayakkara, Kathrin Tyryshkin, Xiaojing Yang, et al.
Neuroendocrinology|May 30, 2017
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown PrimarySimron Singh, Carlo Carnaghi, Roberto Buzzoni, et al.
Lancet (London, England)|June 8, 2024
[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studySimron Singh, Daniel Halperin, Sten Myrehaug, et al.
British Journal of Cancer|March 22, 2021
Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study)Marc Oliva, Pierre H H Schneeberger, Victor Rey, et al.
Pageof 15

Showing results (111-120 of 141) with videos related to

Sort By:
Pageof 15
The Lancet. Oncology|January 19, 2015
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trialRicard Mesía, Michael Henke, Andre Fortin, et al.
The Oncologist|August 3, 2021
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective ReviewDavid L Chan, Emily K Bergsland, Jennifer A Chan, et al.
Cancer Science|October 22, 2017
Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysisNicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, et al.
JAMA Oncology|October 3, 2024
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENsJonathan M Loree, David Chan, Jennifer Lim, et al.
Genome Medicine|April 30, 2020
Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumorRene Quevedo, Anna Spreafico, Jeff Bruce, et al.
Endocrine-Related Cancer|January 22, 2021
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasmsJames C Yao, Jonathan Strosberg, Nicola Fazio, et al.
NAR Cancer|August 4, 2020
Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data miningJina Nanayakkara, Kathrin Tyryshkin, Xiaojing Yang, et al.
Neuroendocrinology|May 30, 2017
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown PrimarySimron Singh, Carlo Carnaghi, Roberto Buzzoni, et al.
Lancet (London, England)|June 8, 2024
[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 studySimron Singh, Daniel Halperin, Sten Myrehaug, et al.
British Journal of Cancer|March 22, 2021
Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study)Marc Oliva, Pierre H H Schneeberger, Victor Rey, et al.
Pageof 15